• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

银屑病治疗的新纪元?生物制剂:事实与争议。

A new era in the management of psoriasis? The biologics: facts and controversies.

机构信息

Department of Dermatology, Hospital Universitari Germans Trias i Pujol, Carretera de Canyet s/n, 08916-Badalona, Spain.

出版信息

Clin Dermatol. 2010 Jan-Feb;28(1):81-7. doi: 10.1016/j.clindermatol.2009.03.002.

DOI:10.1016/j.clindermatol.2009.03.002
PMID:20082956
Abstract

During the last 30 years, the tremendous progress in our knowledge of the pathogenesis of psoriasis has led to the development of new agents, the so-called biologics, that have revolutionized the management of severe psoriasis. Dermatologists and patients see this emerging therapy as a new perspective in the state of the art in managing moderate to severe psoriasis. After a few years of use in daily practice, we may begin to analyze the power of the currently available biologic agents in the management of severe psoriasis from the perspective of facts.

摘要

在过去的 30 年中,我们对银屑病发病机制的认识取得了巨大的进展,这导致了新的治疗药物的发展,即所谓的生物制剂,它们彻底改变了严重银屑病的治疗方法。皮肤科医生和患者认为这种新兴疗法为中重度银屑病的治疗提供了新视角。在日常实践中使用了几年之后,我们也许可以从实际情况的角度开始分析目前可用的生物制剂在严重银屑病治疗中的作用。

相似文献

1
A new era in the management of psoriasis? The biologics: facts and controversies.银屑病治疗的新纪元?生物制剂:事实与争议。
Clin Dermatol. 2010 Jan-Feb;28(1):81-7. doi: 10.1016/j.clindermatol.2009.03.002.
2
Advancements in the treatment of psoriasis: role of biologic agents.银屑病治疗的进展:生物制剂的作用
J Manag Care Pharm. 2004 Jul-Aug;10(4):318-25. doi: 10.18553/jmcp.2004.10.4.318.
3
Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States.美国中重度银屑病生物治疗药物经济学评价
J Dermatolog Treat. 2011 Apr;22(2):65-74. doi: 10.3109/09546630903551258. Epub 2010 May 5.
4
Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials.生物制剂治疗中重度银屑病的疗效:一项随机对照试验的网络荟萃分析。
Br J Dermatol. 2012 Jan;166(1):179-88. doi: 10.1111/j.1365-2133.2011.10583.x. Epub 2011 Nov 11.
5
Combining traditional agents and biologics for the treatment of psoriasis.联合使用传统药物和生物制剂治疗银屑病。
Semin Cutan Med Surg. 2005 Mar;24(1):37-45. doi: 10.1016/j.sder.2005.01.002.
6
Economic evaluation of systemic therapies for moderate to severe psoriasis.中重度银屑病系统治疗的经济学评估
Br J Dermatol. 2009 Jun;160(6):1264-72. doi: 10.1111/j.1365-2133.2008.08962.x. Epub 2008 Dec 15.
7
Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefacept.银屑病的生物治疗——第一波:英夫利昔单抗、依那西普、依法利珠单抗和阿法赛特。
J Drugs Dermatol. 2002 Dec;1(3):303-10.
8
Biologic agents in the treatment of psoriasis.生物制剂在银屑病治疗中的应用
Recent Pat Inflamm Allergy Drug Discov. 2007 Nov;1(3):193-217. doi: 10.2174/187221307782418919.
9
Biologic therapies for psoriasis. A systematic review.银屑病的生物疗法。一项系统综述。
J Rheumatol. 2006 Jul;33(7):1447-51. Epub 2006 May 15.
10
[Treatment of plaque psoriasis with biologics. A meta-analysis of randomized controlled trials].[生物制剂治疗斑块状银屑病。随机对照试验的荟萃分析]
Med Klin (Munich). 2009 Feb 15;104(2):125-36. doi: 10.1007/s00063-009-1024-8. Epub 2009 Feb 26.

引用本文的文献

1
Progression of Quality of Life in Patients with Plaque Psoriasis Who Achieved Three or More Years of Complete Skin Clearance with Guselkumab Treatment: a Post hoc Analysis of the VOYAGE 1 Clinical Trial.接受古塞库单抗治疗实现皮肤完全清除三年或更长时间的斑块状银屑病患者的生活质量进展:VOYAGE 1临床试验的事后分析
Dermatol Ther (Heidelb). 2024 Sep;14(9):2539-2558. doi: 10.1007/s13555-024-01245-6. Epub 2024 Aug 17.
2
Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for ≥ 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial.接受古塞鲁单抗治疗且连续 156 周以上达到完全皮肤清除的斑块状银屑病患者:来自 VOYAGE 1 临床试验的事后分析。
Am J Clin Dermatol. 2024 Mar;25(2):315-325. doi: 10.1007/s40257-023-00816-1. Epub 2023 Oct 7.
3
Riluzole-Loaded Nanostructured Lipid Carriers for Hyperproliferative Skin Diseases.载利鲁唑的纳米结构化脂质载体治疗皮肤过度增殖性疾病。
Int J Mol Sci. 2023 Apr 29;24(9):8053. doi: 10.3390/ijms24098053.
4
Contemporary treatment patterns in plaque psoriasis and psoriatic arthritis.斑块状银屑病和银屑病关节炎的当代治疗模式
Postepy Dermatol Alergol. 2021 Feb;38(2):80-84. doi: 10.5114/ada.2019.91502. Epub 2020 Apr 9.
5
Moderate to severe psoriasis treatment challenges through the era of biological drugs.生物药物时代中重度银屑病的治疗挑战
An Bras Dermatol. 2017 Sep-Oct;92(5):668-674. doi: 10.1590/abd1806-4841.20175603.
6
Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy.生物制剂在银屑病中的超适应证使用:剂量递增、递减和中断生物治疗的疗效和安全性的系统评价。
PLoS One. 2012;7(4):e33486. doi: 10.1371/journal.pone.0033486. Epub 2012 Apr 11.
7
[Monitoring treatment with biologics in non-infectious uveitis].[非感染性葡萄膜炎生物制剂治疗的监测]
Ophthalmologe. 2011 Jan;108(1):21-4. doi: 10.1007/s00347-010-2257-x.
8
Cytokine binding by polysaccharide-antibody conjugates.多糖-抗体缀合物对细胞因子的结合。
Mol Pharm. 2010 Oct 4;7(5):1769-77. doi: 10.1021/mp100150z. Epub 2010 Sep 1.
9
Golimumab and malignancies: true or false association?戈利木单抗与恶性肿瘤:真实关联还是虚假关联?
Med Oncol. 2011 Jun;28(2):641-8. doi: 10.1007/s12032-010-9490-7. Epub 2010 Apr 7.